碳酸锂联合利培酮口服液治疗躁狂发作临床研究

目的评价碳酸锂联合利培酮口服液治疗狂躁发作患者的疗效和安全性。方法将71例躁狂发作患者随机分为两组,碳酸锂联合利培酮口服液组36例和联合氯氮平组35例,进行为期6周的对照研究,采用Bech-Rafaelsen躁狂量表(BRMS)、临床疗效总评量表(CGI)和不良反应症状量表(TESS)评定疗效及安全性。结果联合利培酮口服液组与联合氯氮平组疗效相当(P0.05),而联合利培酮口服液组药物不良反应明显低于氯氮平组。结论碳酸锂联合利培酮口服液治疗躁狂发作疗效好而不良反应少。

Clinical research of lithium carbonate combined risperidone oral solution in treating manic associating

Objective To assess the efficacy and safety of patients by using lithium carbonate associating with risperidone oral solution in treating manic.Methods 71 patients with manic were randomly divided into two groups for 6 weeks of the comparsion study,36 patients of lithium carbonate associating with risperidone oral solution and 35 patients of lithium carbonate associating with clozapine,Bech-Rafaelsdn mania scale （BRMS）,the scale for clinical global impression （CGI） and treatment emergent symptom scale （TESS） were used to assess the efficacy and safety.Results The efficacy had no significant difference between the two groups （P〉0.05）,while the adverse drug reactions of lithium carbonate associating with risperidone oral solution group was significantly lower than that of clozapine group.Conclusion lithium carbonate associating with risperidone oral solution has a better efficacy and mild adverse reactions.